Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 398

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Treatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod

Open access
van Seters, Manon, van Beurden, Marc, ten Kate, Fiebo J.W., Beckmann, Ilse, Ewing, Patricia C., Eijkemans, Marinus J.C., Kagie, Marjolein J., Meijer, Chris J.M., Aaronson, Neil K., KleinJan, Alex, Heijmans-Antonissen, Claudia, Zijlstra, Freek J., Burger, Matthé P.M., Helmerhorst, Theo J.M.·2008·New England Journal of Medicine

Abstract

BACKGROUND: Alternatives to surgery are needed for the treatment of vulvar intraepithelial neoplasia. We investigated the effectiveness of imiquimod 5% cream, a topical immune-response modulator, for the treatment of this condition. METHODS: Fifty-two patients with grade 2 or 3 vulvar intraepithelial neoplasia were randomly assigned to receive either imiquimod or placebo, applied twice weekly for 16 weeks. The primary outcome was a reduction of more than 25% in lesion size at 20 weeks. Secondary outcomes were histologic regression, clearance of human papillomavirus (HPV) from the lesion, changes in immune cells in the epidermis and dermis of the vulva, relief of symptoms, improvement of quality of life, and durability of response. Reduction in lesion size was classified as complete response (elimination), strong partial response (76 to 99% reduction), weak partial response (26 to 75% reduction), or no response (< or =25% reduction). The follow-up period was 12 months. RESULTS: Lesion size was reduced by more than 25% at 20 weeks in 21 of the 26 patients (81%) treated with imiquimod and in none of those treated with placebo (P<0.001). Histologic regression was significantly greater in the imiquimod group than in the placebo group (P<0.001). At baseline, 50 patients (96%) tested positive for HPV DNA. HPV cleared from the lesion in 15 patients in the imiquimod group (58%), as compared with 2 in the placebo group (8%) (P<0.001). The number of immune epidermal cells increased significantly and the number of immune dermal cells decreased significantly with imiquimod as compared with placebo. Imiquimod reduced pruritus and pain at 20 weeks (P=0.008 and P=0.004, respectively) and at 12 months (P=0.04 and P=0.02, respectively). The lesion progressed to invasion (to a depth of <1 mm) in 3 of 49 patients (6%) followed for 12 months (2 in the placebo group and 1 in the imiquimod group). Nine patients, all treated with imiquimod, had a complete response at 20 weeks and remained free from disease at 12 months. CONCLUSIONS: Imiquimod is effective in the treatment of vulvar intraepithelial neoplasia. (Current Controlled Trials number, ISRCTN11290871 [controlled-trials.com].).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa072685

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 398

Metadata

Authors
van Seters, M., van Beurden, M., ten Kate, F. J. W., Beckmann, I., Ewing, P. C., Eijkemans, M. J. C., Kagie, M. J., Meijer, C. J. M., Aaronson, N. K., KleinJan, A., Heijmans-Antonissen, C., Zijlstra, F. J., Burger, M. P. M., & Helmerhorst, T. J. M.
Venue
New England Journal of Medicine
Published
2008-04-03
Volume
358
Issue
14
Pages
1465-1473
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2097648465
Cited by
398
References
21
FWCI
30.71
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod. https://app.cochat.ai/papers/10.1056/nejmoa072685
The paper
van Seters, M., van Beurden, M., ten Kate, F. J. W., Beckmann, I., Ewing, P. C., Eijkemans, M. J. C., Kagie, M. J., Meijer, C. J. M., Aaronson, N. K., KleinJan, A., Heijmans-Antonissen, C., Zijlstra, F. J., Burger, M. P. M., & Helmerhorst, T. J. M. (2008). Treatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod. New England Journal of Medicine. https://doi.org/10.1056/nejmoa072685

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.